TELOMIR PHARMACEUTICALS, INC.

Altre lingue Telomir Pharmaceuticals, Inc.

Azioni

TELO

US87975F1049

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 21/05/2024			Variaz. 5gg	Var. 1 gen.
5,7 ^USD	-5,63%		-9,60%	0,00%

13/05	Telomir Pharmaceuticals, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
16/04	Telomir Pharmaceuticals, Inc. presenta gli interessanti dati preclinici sul farmaco per l'inversione dell'età Telomir-1 all'evento del National Press Club di Washington.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support	16/05
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1	07/05
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.	16/04
Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C	16/04
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors	12/04
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024	02/04
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines	26/03
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines	26/03
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th	22/03
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science	14/03
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference	07/03
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore Conference	07/03
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal	05/03
Telomir Pharmaceuticals Announces Closing of Initial Public Offering	13/02
Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to NASDAQ Composite Index	12/02
Telomir Pharmaceuticals, Inc. has completed an IPO in the amount of $7 million.	08/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

-40% Offerta a tempo limitato: i nostri abbonamenti ti guidano verso i migliori investimenti di domani.

APPROFITTANE ORA